Table 3 Adjusted rate ratios of acute myocardial infarction for current use of celecoxib and rofecoxib according to the presence of a previous myocardial infarction and the dose prescribed.

	No previous MI				Previous MI
	Cases	Controls	Adjusted RR* (95% CI)	p Values	Cases	Controls	Adjusted RR* (95% CI)	p Values
No use†	793	18502	1.00 (reference)		139	1145	1.00 (reference)
Celecoxib	287	6321	1.03 (0.88 to 1.20)		82	472	1.40 (1.06 to 1.84)
Low dose‡	208	4704	1.01 (0.86 to 1.20)	0.75	57	349	1.32 (0.96 to 1.82)	0.50
High dose§	79	1617	1.06 (0.83 to 1.36)		25	123	1.60 (1.00 to 2.54)
Rofecoxib	239	4295	1.23 (1.05 to 1.45)		58	308	1.59 (1.15 to 2.18)
Low dose‡	218	4010	1.20 (1.02 to 1.42)	0.20	50	287	1.48 (1.06 to 2.07)	0.14
High dose§	21	285	1.66 (1.04 to 2.63)		8	21	2.99 (1.25 to 7.14)

MI, myocardial infarction.

*Adjusted for age at index (continuous variable); sex, hypertension, coronary artery disease, cerebrovascular disease, peripheral vascular disease, congestive heart failure, diabetes, respiratory illness, gastrointestinal ulcer disease, thyroid disorders, depression/psychiatric illness and cancer, in the year preceding cohort entry; use of concomitant therapy including antilipidaemic agents, anticoagulants, aspirin and past use of non‐steroidal anti‐inflammatory drugs, in the year preceding cohort entry; healthcare utilisation including hospitalisations, outpatient visits to any doctor and outpatient cardiologist visits, in the year preceding the index date; number of different drugs taken, chronic disease score and Charlson index in the year preceding the index date. Rate ratios are for current users compared with no use in the year preceding the index date.

†No use in the year preceding the index date.

‡⩽200 and ⩽25 mg/day for celecoxib and rofecoxib, respectively.

§>200 and >25 mg/day for celecoxib and rofecoxib, respectively.